EssilorLuxottica boosted its myopia portfolio at the recent China International Import Expo in Shanghai, launching Essilor Stellest 2.0 in Greater China, with other key markets to follow in 2026.

Building on the success of the Essilor Stellest lens, the first FDA market-authorised spectacle lens clinically proven to slow myopia progression in children, the 2.0 iteration delivers significantly higher efficacy in slowing the axial elongation of the eye, the company said. “A recent study (12-month on-file results from a prospective, randomised, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children) shows the new design further supports effective myopia management by generating a stronger optical signal delivering double the mean optical power.”

The Essilor Stellest plano pair lenses are moving towards early intervention by introducing clinically validated solutions for children at risk of developing myopia, Essilor said. “Clinical research shows that postponing myopia onset by just one year can offer benefits comparable to over two years of slowed progression.” One of the world's first randomised, controlled, independent trials on plano lenses for delaying myopia onset found that children aged 6–12 at risk of myopia who wore Essilor Stellest plano pair lenses for more than 30 hours per week experienced slower axial elongation. “This innovation marks a major step from myopia management toward evidence-based prevention,” the company said.

EssilorLuxottica also showcased the Essilor Stellest Smartglasses for the first time at the Shanghai expo, expanding its smart technologies to the Essilor Stellest brand. Equipped with Essilor Stellest lenses, the glasses track wearing time and patterns, providing behavioural insights and helping with wearing compliance, critical to myopia management, Essilor said. The smartglasses will be available in mainland China starting in the first quarter of 2026, with no dates for other markets available yet.